InvestmentApr 27, 2026, 07:12 AM
COAG Files S-1/A for IPO of 11.76M Shares; Price $16-18
AI Summary
Hemab Therapeutics Holdings, Inc. filed an S-1/A registration statement for its initial public offering, proposing to sell 11,764,706 shares of common stock at an estimated price range of $16.00 to $18.00 per share. The company expects to raise approximately $180.3 million in net proceeds, which will be used to fund clinical development of its lead assets, sutacimig and HMB-002, and other corporate purposes. Hemab, a clinical-stage biotechnology company focused on blood coagulation disorders, recently completed a corporate reorganization in March 2026 and has applied to list its shares on Nasdaq under the symbol "COAG".
Key Highlights
- Hemab Therapeutics Holdings, Inc. is offering 11,764,706 shares of common stock in its IPO.
- Estimated initial public offering price per share is between $16.00 and $18.00.
- Anticipated net proceeds from the offering are approximately $180.3 million.
- Company has applied to list common stock on Nasdaq Global Select Market under "COAG".
- Completed a corporate reorganization in March 2026, making Hemab ApS a wholly-owned subsidiary.
- Lead asset sutacimig (HMB-001) is in Phase 1/2 and Phase 2 clinical development.
- Second asset HMB-002 is in Phase 1/2 clinical development for Von Willebrand Disease.
- Reported a net loss of $(63.9) million for the year ended December 31, 2025.